Table 1.

Summary of the efficacy responses after 12 and 24 weeks treatment

		Once-daily dosing			Twice-daily dosing

	Placebo	50mg	100mg	200mg	25mg	50mg	100mg
	n=86	n=82	n=85	n=86	n=86	n=85	n=84

Week 12
ACR20, NRI¹, %	44	56	64*	69**	57	60	79***
ACR50, NRI, %	15	33*	38**	43***	28*	34*	55***
ACR70, NRI, %	8	16	21	24*	14	19	31**
DAS28(CRP), mean change from BL², LOCF³	−1.2	−1.8**	−2.2***	−2.5***	−1.9**	−2.1***	−2.8***
CDAI⁴, mean change from BL, LOCF	−17	−20	−24**	−26***	−21*	−23**	−29***
Week 24
ACR20, NRI, %	42	55	61*	73***	56	60*	80***
ACR50, NRI, %	16	35**	47***	50***	35**	35**	55***
ACR70, NRI, %	9	22*	33**	29**	21*	24*	39***
DAS28(CRP), mean change from BL, LOCF	−1.2	−2.0***	−2.7***	−2.8***	−2.2***	−2.4***	−3.2***
CDAI, mean change from BL, LOCF	−16	−21**	−29***	−29***	−24***	−27***	−32***

*p<0.05 vs. placebo; **p<0.01 vs. placebo; ***p<0.001 vs. placebo; ACR scores based on ITT analysis. ¹Non-responder imputation. ²Baseline. ³Last observation carried forward. ⁴Clinical Disease Activity Index.